NCT01716975

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 767 (actual)
• Sponsor: FORUM Pharmaceuticals Inc · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Conditions

• Schizophrenia
• Impaired Cognition

Interventions

Type	Name	Description
DRUG	EVP-6124	Arms 1, 2
DRUG	Placebo	Arm 3

Timeline

• Start date: 2012-10-01
• Primary completion: 2016-02-01
• Completion: 2016-02-01
• First posted: 2012-10-30
• Last updated: 2016-05-03

Locations

106 sites across 12 countries: United States, Argentina, Australia, Brazil, Colombia, Italy, Mexico, Poland, Romania, Russia, Ukraine, United Kingdom